Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Neil Gregory Almstead sold 881 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $67,352.45. Following the completion of the sale, the insider owned 115,196 shares of the company’s stock, valued at approximately $8,806,734.20. This trade represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Neil Gregory Almstead also recently made the following trade(s):

• On Thursday, January 8th, Neil Gregory Almstead sold 59 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total transaction of $4,510.55.
• On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $4,028.96.
• On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $79,494.48.
• On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $4,155.30.
• On Tuesday, January 6th, Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $98,419.05.
• On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The shares were sold at an average price of $80.18, for a total value of $2,852,162.96.
• On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The stock was sold at an average price of $83.44, for a total value of $6,001,672.32.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock traded up $0.06 during midday trading on Monday, hitting $77.59. The company had a trading volume of 2,631,928 shares, compared to its average volume of 1,795,906. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The business’s 50 day simple moving average is $76.61 and its two-hundred day simple moving average is $62.91. The stock has a market cap of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The firm had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.39) EPS. On average, sell-side analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PTCT. Empowered Funds LLC bought a new stake in shares of PTC Therapeutics in the first quarter worth about $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of PTC Therapeutics by 11.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after purchasing an additional 18,504 shares in the last quarter. Intech Investment Management LLC grew its position in shares of PTC Therapeutics by 62.8% in the 1st quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock valued at $2,003,000 after purchasing an additional 15,167 shares during the period. Acadian Asset Management LLC increased its stake in PTC Therapeutics by 6.1% during the 1st quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock worth $1,904,000 after purchasing an additional 2,140 shares in the last quarter. Finally, Strs Ohio acquired a new stake in PTC Therapeutics during the 1st quarter worth approximately $438,000.

Analysts Set New Price Targets

Several research firms recently issued reports on PTCT. Wells Fargo & Company increased their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. The Goldman Sachs Group upped their price objective on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Finally, Citigroup increased their price objective on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.